TomoTherapy® System Provides Favorable Cosmetic Outcomes Without Compromising Efficacy in Low-Risk Breast Cancer Patients

Sunnyvale, California (ots/PRNewswire) -

Accuray Incorporated (NASDAQ: ARAY) announced today preliminary
results from a prospective, phase II trial evaluating once-daily
accelerated partial breast irradiation (APBI) in patients treated
with the TomoTherapy® System. The study, published in the June issue
of the peer-reviewed AntiCancer Research, International Journal of
Cancer Research and Treatment, reported no recurrence of cancer in
the treated breast at median follow-up of 34 months. Additionally,
more than 95 percent of patients and their physicians rated cosmesis
-- preservation of the normal appearance of the breast -- as
good/excellent.

(Logo: http://photos.prnewswire.com/prnh/20151126/291246LOGO )

(Photo: http://photos.prnewswire.com/prnh/20160721/391950 )

"The phase II trial results are very encouraging for a carefully
selected patient population, and should be considered by all
radiation oncologists when evaluating APBI treatments for their
low-risk patients," said Prof. Ugo De Paula, Department of Radiation
Oncology, San Giovanni-Addolorata Hospital, Rome-Italy. "In our
experience we found there was extremely good patient compliance with
their APBI treatment regimen because of a very short, 10-day schedule
and well-tolerated treatments. We believe that using daily image
guidance, which is unique to the TomoTherapy System, is essential for
the precise identification of the tumor bed and reproducibility of
treatment."

The study titled, "Once Daily Accelerated Partial Breast
Irradiation: Preliminary Results with Helical TomoTherapy," provides
results for 111 patients treated with APBI following lumpectomy. It
also demonstrated that:

- Delivering the dose once a day over 10 days (others studies use 10
fractions twice-daily) could be a contributing factor to better
cosmetic outcomes and lower toxicity. This is made possible because
of the integrated image guidance of the TomoTherapy System and its
excellent dose homogeneity;
- Patient compliance was remarkable as all patients completed the
treatment without interruption;
- Treatments were very well tolerated with minimal acute or late side
effects.

"The TomoTherapy System is proving itself to be an excellent
breast radiotherapy device. In fact, some sites have purchased the
system to use solely for breast radiotherapy," said Fabienne
Hirigoyenberry-Lanson, PhD, vice president medical affairs, at
Accuray. "Studies such as the one undertaken by Dr. de Paula and his
colleagues reinforce the benefits which the TomoTherapy System can
provide and highlight why customers worldwide rely on the system as
their mainstream radiation treatment device."

The TomoTherapy System is the only radiation system specifically
designed for image-guided intensity-modulated radiation therapy
(IMRT). Leveraging a CT scanner-based platform, TomoHelical(TM) mode
enables continuous delivery from 360 degrees around the patient with
highly conformal and homogeneous dose to the tumor. A clinician can
also choose to deliver treatment from specific fixed angles via
TomoDirect(TM) mode. These unique features, combined with daily 3D
image guidance, enable physicians to efficiently deliver highly
accurate, individualized dose distributions which precisely conform
to the shape of the patient's tumor while minimizing dose to normal,
healthy tissue for a variety of cancer types, including breast
cancer. This is especially important for women diagnosed with cancer
in the left breast, where the tumor may be close to critical organs
such as the heart.

For further information on the TomoTherapy System, visit http://ww
w.accuray.com/solutions/treatment-delivery/tomotherapy-treatment-deli
very/h-series

About the Phase II Trial

The study was designed to assess the role of once-daily
accelerated partial breast irradiation in terms of cosmetic and local
results. The primary endpoints of this trial were breast tumor
recurrence and toxicity. Secondary outcomes were rates of adverse
cosmesis, quality of life and compliance. Patients who had previously
undergone breast-conserving surgery were enrolled in the study.
Radiation treatments were administered in 10 daily fractions of 3.85
Gy.

Important Safety Information

For Important Safety Information please refer to
http://www.accuray.com/safety-statement-radiation-treatment

About Accuray

Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology
company that develops, manufactures and sells precise, innovative
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation therapy
and radiosurgery treatments. For more information, please visit
http://www.accuray.com .

Safe Harbor Statement

Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to the
"safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements in this press release relate,
but are not limited, to clinical applications, clinical results,
patient outcomes and Accuray's leadership position in radiation
oncology innovation and technologies. Forward-looking statements are
subject to risks and uncertainties that could cause actual results to
differ materially from expectations, including but not limited to the
risks detailed from time to time under the heading "Risk Factors" in
the company's report on Form 10-K, filed on August 28, 2015, the
company's reports on Form 10-Q, filed on November 5, 2015 and
February 1, 2016 and April 29, 2016, and the company's other filings
with the SEC.

Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events. The
company assumes no obligation to update forward-looking statements to
reflect actual performance or results, changes in assumptions or
changes in other factors affecting forward-looking information,
except to the extent required by applicable securities laws.
Accordingly, investors should not put undue reliance on any
forward-looking statements.

ots Originaltext: Accuray
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Sancie Nakarat
Director Marketing Communications
Accuray
+33(0)6-81-36-84-34
snakarat@accuray.com